Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study.

Détails

Ressource 1Télécharger: 27746888_BIB_1CF652058495.pdf (130.69 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_1CF652058495
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study.
Périodique
Rare Tumors
Auteur(s)
Ugurluer G., Miller R.C., Li Y., Thariat J., Ghadjar P., Schick U., Ozsahin M.
ISSN
2036-3605 (Print)
ISSN-L
2036-3605
Statut éditorial
Publié
Date de publication
2016
Peer-reviewed
Oui
Volume
8
Numéro
3
Pages
6502
Langue
anglais
Notes
Publication types: ARTICLE
Publication Status: epublish
Résumé
Primary hepatic lymphoma (PHL) is a rare malignancy. We aimed to assess the clinical profile, outcome and prognostic factors in PHL through the Rare Cancer Network (RCN). A retrospective analysis of 41 patients was performed. Median age was 62 years (range, 23-86 years) with a male-to-female ratio of 1.9:1.0. Abdominal pain or discomfort was the most common presenting symptom. Regarding B-symptoms, 19.5% of patients had fever, 17.1% weight loss, and 9.8% night sweats. The most common radiological presentation was multiple lesions. Liver function tests were elevated in 56.1% of patients. The most common histopathological diagnosis was diffuse large B-cell lymphoma (65.9%). Most of the patients received Chop-like (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens; 4 patients received radiotherapy (dose range, 30.6-40.0 Gy). Median survival was 163 months, and 5- and 10-year overall survival rates were 77 and 59%, respectively. The 5- and 10-year disease-free and lymphoma-specific survival rates were 69, 56, 87 and 70%, respectively. Multivariate analysis revealed that fever, weight loss, and normal hemoglobin level were the independent factors influencing the outcome. In this retrospective multicenter RCN study, patients with PHL had a relatively better prognosis than that reported elsewhere. Multicenter prospective studies are still warranted to establish treatment guidelines, outcome, and prognostic factors.
Pubmed
Open Access
Oui
Création de la notice
25/10/2016 17:36
Dernière modification de la notice
20/08/2019 12:53
Données d'usage